These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 16982192)
1. Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors. Senger S; Convery MA; Chan C; Watson NS Bioorg Med Chem Lett; 2006 Nov; 16(22):5731-5. PubMed ID: 16982192 [TBL] [Abstract][Full Text] [Related]
2. Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. Zbinden KG; Anselm L; Banner DW; Benz J; Blasco F; Décoret G; Himber J; Kuhn B; Panday N; Ricklin F; Risch P; Schlatter D; Stahl M; Thomi S; Unger R; Haap W Eur J Med Chem; 2009 Jul; 44(7):2787-95. PubMed ID: 19200624 [TBL] [Abstract][Full Text] [Related]
3. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors. Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987 [TBL] [Abstract][Full Text] [Related]
4. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors. Van Huis CA; Bigge CF; Casimiro-Garcia A; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Narasimhan LS; Schaum RP; Zhang E; Bryant JW; Haarer S; Janiczek N; Leadley RJ; McClanahan T; Thomas Peterson J; Welch KM; Edmunds JJ Chem Biol Drug Des; 2007 Jun; 69(6):444-50. PubMed ID: 17581239 [TBL] [Abstract][Full Text] [Related]
5. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190 [TBL] [Abstract][Full Text] [Related]
7. Sulfonamide-related conformational effects and their importance in structure-based design. Senger S; Chan C; Convery MA; Hubbard JA; Shah GP; Watson NS; Young RJ Bioorg Med Chem Lett; 2007 May; 17(10):2931-4. PubMed ID: 17336062 [TBL] [Abstract][Full Text] [Related]
8. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: exploration of 5-6 fused rings as alternative S1 moieties. Yoshikawa K; Yokomizo A; Naito H; Haginoya N; Kobayashi S; Yoshino T; Nagata T; Mochizuki A; Osanai K; Watanabe K; Kanno H; Ohta T Bioorg Med Chem; 2009 Dec; 17(24):8206-20. PubMed ID: 19884015 [TBL] [Abstract][Full Text] [Related]
10. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508 [TBL] [Abstract][Full Text] [Related]
11. Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors. Bauer SM; Goldman EA; Huang W; Su T; Wang L; Woolfrey J; Wu Y; Zuckett JF; Arfsten A; Huang B; Kothule J; Lin J; May B; Sinha U; Wong PW; Hutchaleelaha A; Scarborough RM; Zhu BY Bioorg Med Chem Lett; 2004 Aug; 14(15):4045-50. PubMed ID: 15225723 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties. Yoshikawa K; Kobayashi S; Nakamoto Y; Haginoya N; Komoriya S; Yoshino T; Nagata T; Mochizuki A; Watanabe K; Suzuki M; Kanno H; Ohta T Bioorg Med Chem; 2009 Dec; 17(24):8221-33. PubMed ID: 19900814 [TBL] [Abstract][Full Text] [Related]
13. Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core. Hangeland JJ; Cheney DL; Friends TJ; Swartz S; Levesque PC; Rich AJ; Sun L; Bridal TR; Adam LP; Normandin DE; Murugesan N; Ewing WR Bioorg Med Chem Lett; 2008 Jan; 18(2):474-8. PubMed ID: 18160281 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405 [TBL] [Abstract][Full Text] [Related]
15. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors. Shi Y; Zhang J; Shi M; O'Connor SP; Bisaha SN; Li C; Sitkoff D; Pudzianowski AT; Chong S; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD Bioorg Med Chem Lett; 2009 Aug; 19(15):4034-41. PubMed ID: 19541481 [TBL] [Abstract][Full Text] [Related]
16. Fragment-based discovery of JAK-2 inhibitors. Antonysamy S; Hirst G; Park F; Sprengeler P; Stappenbeck F; Steensma R; Wilson M; Wong M Bioorg Med Chem Lett; 2009 Jan; 19(1):279-82. PubMed ID: 19019674 [TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of p38 inhibitors via computer-assisted drug design. Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737 [TBL] [Abstract][Full Text] [Related]
18. The discrete role of chlorine substitutions in the conformation and supramolecular architecture of arylsulfonamides. Fernandes WB; Aragão AQ; Martins FT; Noda-Perez C; Lariucci C; Napolitano HB Acta Crystallogr C; 2011 Jul; 67(Pt 7):o226-9. PubMed ID: 21727630 [TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to human isoform II. Menchise V; De Simone G; Di Fiore A; Scozzafava A; Supuran CT Bioorg Med Chem Lett; 2006 Dec; 16(24):6204-8. PubMed ID: 17000110 [TBL] [Abstract][Full Text] [Related]
20. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity. Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]